140383772	140383772	CD	B-NP	O
|	|	NN	I-NP	O
NHUAH	NHUAH	NN	I-NP	O
|	|	NN	I-NP	O
71871773	71871773	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
799792	799792	CD	B-NP	O
|	|	CC	I-NP	O
10/15/2000	10/15/2000	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
ASTHMA	ASTHMA	NNP	I-NP	I-protein
EXACERBATION	EXACERBATION	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
7/14/2000	7/14/2000	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/6/2000	5/6/2000	CD	B-NP	O
PRINCIPAL	PRINCIPAL	JJ	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
ASTHMA	ASTHMA	NN	B-NP	O
EXACERBATION	EXACERBATION	NN	I-NP	O
.	.	.	O	O

SECONDARY	SECONDARY	NN	B-NP	O
DIAGNOSES	DIAGNOSES	NNS	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
MORBID	MORBID	NNP	I-NP	O
OBESITY	OBESITY	NNP	I-NP	O
.	.	.	O	O

2	2	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
HISTORY	HISTORY	NN	I-NP	B-protein
OF	OF	IN	B-PP	I-protein
RECURRENT	RECURRENT	NNP	B-NP	O
DEEP	DEEP	NNP	I-NP	O
VENOUS	VENOUS	NNP	I-NP	O
THROMBOSES/PULMONARY	THROMBOSES/PULMONARY	NNP	I-NP	O
EMBOLUS	EMBOLUS	NNP	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
47	47	CD	I-NP	O
year-old	year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
long-standing	long-standing	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
asthma	asthma	NN	B-NP	O
and	and	CC	O	O
chronic	chronic	JJ	B-NP	O
obstructive	obstructive	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
disease	disease	NN	I-NP	O
who	who	WP	B-NP	O
now	now	RB	B-ADVP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
cough	cough	NN	B-NP	O
,	,	,	O	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
increased	increase	VBD	B-VP	O
wheezing	wheeze	VBG	I-VP	O
times	time	NNS	B-NP	O
three	three	CD	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
morbidly	morbidly	RB	I-NP	O
obese	obese	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
long-standing	long-standing	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
asthma	asthma	NN	B-NP	O
since	since	IN	B-PP	O
childhood	childhood	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-protein
most	most	RBS	I-NP	O
recent	recent	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
in	in	IN	B-PP	O
October	October	NNP	B-NP	O
of	of	IN	B-PP	O
1998	1998	CD	B-NP	O
revealed	reveal	VBD	B-VP	O
an	an	DT	B-NP	O
FVC	FVC	NN	I-NP	O
of	of	IN	B-PP	O
2.6	2.6	CD	B-NP	O
and	and	CC	I-NP	O
FEV1	FEV1	CD	I-NP	O
of	of	IN	B-PP	O
1.43	1.43	CD	B-NP	O
and	and	CC	O	O
an	an	DT	B-NP	O
FEV1/FVC	FEV1/FVC	NN	I-NP	O
of	of	IN	B-PP	O
66	66	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-protein
most	most	RBS	I-NP	O
recent	recent	JJ	I-NP	O
hospitalization	hospitalization	NN	I-NP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
asthma	asthma	NN	I-NP	O
exacerbation	exacerbation	NN	I-NP	O
was	be	VBD	B-VP	O
October	October	NNP	B-NP	O
of	of	IN	B-PP	O
2000	2000	CD	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Joh	Joh	NNP	I-NP	O
Memorial	Memorial	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
She	She	NNP	I-NP	O
has	have	VBZ	B-VP	O
no	no	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
intubations	intubation	NNS	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
medical	medical	JJ	I-NP	O
intensive	intensive	JJ	I-NP	O
care	care	NN	I-NP	O
unit	unit	NN	I-NP	O
admissions	admission	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
home	home	NN	I-NP	O
oxygen	oxygen	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
repeated	repeat	VBN	B-NP	O
deep	deep	JJ	I-NP	O
venous	venous	JJ	I-NP	O
thromboses	thrombos	NNS	I-NP	O
,	,	,	O	O
particularly	particularly	RB	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
pulmonary	pulmonary	JJ	B-NP	O
embolus	embolus	NN	I-NP	O
in	in	IN	B-PP	O
1975	1975	CD	B-NP	O
and	and	CC	I-NP	O
1991	1991	CD	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
since	since	IN	B-PP	O
1991	1991	CD	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
last	last	JJ	I-NP	O
admission	admission	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
deep	deep	JJ	I-NP	O
venous	venous	JJ	I-NP	O
thrombosis	thrombosis	NN	I-NP	O
in	in	IN	B-PP	O
1997	1997	CD	B-NP	O
.	.	.	O	O

Three	Three	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
noted	note	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
felt	feel	VBD	B-VP	O
unwell	unwell	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
cough	cough	NN	I-NP	O
productive	productive	JJ	B-ADJP	O
of	of	IN	B-PP	O
yellow	yellow	JJ	B-NP	O
sputum	sputum	NN	I-NP	O
,	,	,	O	O
increased	increase	VBD	B-VP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
and	and	CC	I-NP	O
wheezing	wheezing	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
attributed	attribute	VBD	B-VP	O
the	the	DT	B-NP	O
cough	cough	NN	I-NP	O
and	and	CC	O	O
wheeze	wheeze	VB	B-VP	O
to	to	TO	B-PP	O
exposure	exposure	NN	B-NP	O
to	to	TO	B-PP	O
dust	dust	NN	B-NP	O
and	and	CC	I-NP	O
mold	mold	NN	I-NP	O
on	on	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
nursing	nursing	NN	I-NP	O
facility	facility	NN	I-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
lives	live	VBZ	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
diagnosed	diagnose	VBN	I-VP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
upper	upper	JJ	I-NP	O
respiratory	respiratory	JJ	I-NP	O
infection	infection	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
skilled	skilled	JJ	I-NP	O
nursing	nursing	NN	I-NP	O
facility	facility	NN	I-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
resides	reside	VBZ	B-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
one	one	CD	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Doxycycline	Doxycycline	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
night	night	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Linverl	Linverl	NNP	I-NP	O
Health	Health	NNP	I-NP	O
Services	Service	NNPS	I-NP	O
on	on	IN	B-PP	O
August	August	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
for	for	IN	B-PP	O
increased	increase	VBN	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	I-NP	O
cough	cough	NN	I-NP	O
and	and	CC	I-NP	O
wheezing	wheezing	NN	I-NP	O
,	,	,	O	O
not	not	RB	B-VP	O
relieved	relieve	VBN	I-VP	O
by	by	IN	B-PP	O
two	two	CD	B-NP	O
Ventolin	Ventolin	NN	I-NP	O
nebulizers	nebulizer	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
notes	note	VBZ	B-VP	O
no	no	DT	B-NP	O
associated	associate	VBN	I-NP	O
symptoms	symptom	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
sore	sore	JJ	I-NP	O
throat	throat	NN	I-NP	O
,	,	,	I-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	I-NP	O
vomiting	vomiting	NN	I-NP	O
,	,	,	I-NP	O
diarrhea	diarrhea	NN	I-NP	O
,	,	,	I-NP	O
fever	fever	NN	I-NP	O
or	or	CC	I-NP	O
hemoptysis	hemoptysis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
afebrile	afebrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
known	known	JJ	I-NP	O
ill	ill	JJ	I-NP	O
contacts	contact	NNS	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
room	room	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
peak	peak	NN	I-NP	O
flow	flow	NN	I-NP	O
of	of	IN	B-PP	O
180	180	CD	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
peak	peak	NN	I-NP	O
flow	flow	NN	I-NP	O
of	of	IN	B-PP	O
350	350	CD	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
an	an	DT	B-NP	O
Albuterol	Albuterol	NNP	I-NP	O
nebulizer	nebulizer	NN	I-NP	O
,	,	,	O	O
Atrovent	Atrovent	JJ	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
times	time	NNS	I-NP	O
one	one	CD	B-NP	O
,	,	,	O	O
Levofloxacin	Levofloxacin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
times	time	NNS	I-NP	O
one	one	CD	B-NP	O
,	,	,	O	O
Prednisone	Prednisone	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
times	time	NNS	I-NP	O
one	one	CD	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
As	As	IN	B-SBAR	O
above	above	RB	B-ADVP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
asthma	asthma	NN	B-NP	O
and	and	CC	O	O
chronic	chronic	JJ	B-NP	O
obstructive	obstructive	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
in	in	IN	B-PP	O
1997	1997	CD	B-NP	O
.	.	.	O	O

2	2	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Deep	Deep	NN	I-NP	O
venous	venous	JJ	I-NP	O
thromboses	thrombos	NNS	I-NP	O
which	which	WDT	B-NP	O
have	have	VBP	B-VP	O
been	be	VBN	I-VP	O
recurrent	recurrent	JJ	B-ADJP	O
since	since	IN	B-PP	O
age	age	NN	B-NP	O
21	21	CD	I-NP	O
with	with	IN	B-PP	O
left	left	JJ	B-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
swelling	swelling	NN	I-NP	O
.	.	.	O	O

3	3	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Pulmonary	Pulmonary	JJ	I-NP	O
embolus	embolus	NN	I-NP	O
in	in	IN	B-PP	O
1975	1975	CD	B-NP	O
and	and	CC	I-NP	O
1991	1991	CD	I-NP	O
.	.	.	O	O

4	4	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Abortion/placental	Abortion/placental	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
.	.	.	O	O

5	5	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Vaginal	Vaginal	NNP	I-NP	O
bleeding	bleeding	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Obesity	Obesity	NNP	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Allergic	Allergic	JJ	I-NP	O
rhinitis	rhinitis	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Colace	Colace	NNP	I-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
2	2	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Xenical	Xenical	JJ	I-NP	O
120	120	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
3	3	CD	I-NP	O
-RRB-	-RRB-	HYPH	B-NP	O
Diazide	Diazide	NNP	I-NP	O
one	one	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

4	4	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	B-protein
Uniphyl	Uniphyl	NNP	B-NP	I-protein
800	800	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
5	5	CD	I-NP	I-protein
-RRB-	-RRB-	SYM	I-NP	I-protein
TUMS	TUMS	NN	I-NP	I-protein
625	625	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	B-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
6	6	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Lasix	Lasix	NNP	I-NP	I-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
7	7	CD	I-NP	I-protein
-RRB-	-RRB-	SYM	O	O
Pyridoxine	Pyridoxine	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Folate	Folate	NN	I-NP	O
3	3	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Celebrex	Celebrex	NNP	I-NP	B-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
b.i.d.	b.i.d.	RB	B-NP	I-protein
10	10	CD	I-NP	I-protein
-RRB-	-RRB-	SYM	I-NP	I-protein
Wellbutrin	Wellbutrin	NN	I-NP	I-protein
200	200	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
11	11	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Iron	Iron	NNP	I-NP	I-protein
325	325	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
12	12	CD	I-NP	I-protein
-RRB-	-RRB-	:	O	I-protein
Coumadin	Coumadin	NN	B-NP	I-protein
8	8	CD	B-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	B-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
13	13	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Albuterol	Albuterol	NNP	I-NP	O
nebulizers	nebulizer	NNS	I-NP	O
90	90	CD	B-NP	O
mg	mg	NN	I-NP	O
inhaler	inhaler	NN	I-NP	O
,	,	,	O	O
2	2	CD	B-NP	O
puffs	puff	NNS	I-NP	O
q.i.d.	q.i.d.	VBP	B-VP	O
p.r.n.	p.r.n.	NN	B-NP	O
14	14	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Albuterol	Albuterol	NN	I-NP	O
nebulizers	nebulizer	NNS	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Prednisone	Prednisone	NN	I-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
t.i.d.	t.i.d.	FW	I-NP	O
16	16	CD	I-NP	O
-RRB-	-RRB-	SYM	I-NP	O
Levofloxacin	Levofloxacin	NN	I-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

17	17	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Magnesium	Magnesium	NN	I-NP	B-protein
oxide	oxide	NN	I-NP	I-protein
840	840	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	B-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
18	18	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Flovent	Flovent	NNP	I-NP	I-protein
660	660	CD	I-NP	I-protein
mcg	mcg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
19	19	CD	I-NP	I-protein
-RRB-	-RRB-	HYPH	B-NP	I-protein
Serevent	Serevent	NN	I-NP	I-protein
20	20	CD	I-NP	I-protein
mcg	mcg	NN	I-NP	I-protein
inhaled	inhale	VBD	B-VP	I-protein
2	2	CD	B-NP	I-protein
puffs	puff	NNS	I-NP	I-protein
b.i.d.	b.i.d.	JJ	B-NP	O
ALLERGIES	ALLERGIES	NNS	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
allergic	allergic	JJ	B-ADJP	O
to	to	TO	B-PP	O
horse	horse	NN	B-NP	O
serum	serum	NN	I-NP	O
which	which	WDT	B-NP	O
leads	lead	VBZ	B-VP	O
to	to	TO	B-PP	O
anaphylaxis	anaphylaxis	NN	B-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Father	Father	NNP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
cerebrovascular	cerebrovascular	JJ	I-NP	O
accident	accident	NN	I-NP	O
at	at	IN	B-PP	O
age	age	NN	B-NP	O
35	35	CD	I-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
arterial	arterial	JJ	B-NP	O
thromboses	thrombos	NNS	I-NP	O
.	.	.	O	O

Mother	Mother	NNP	B-NP	O
has	have	VBZ	B-VP	O
breast	breast	NN	B-NP	O
cancer	cancer	NN	I-NP	O
.	.	.	O	O

Both	Both	DT	B-NP	O
parents	parent	NNS	I-NP	O
are	be	VBP	B-VP	O
still	still	RB	I-VP	O
living	live	VBG	I-VP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
lives	live	VBZ	B-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
separated	separate	VBN	B-VP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
husband	husband	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
smokes	smoke	VBZ	B-VP	O
three	three	CD	B-NP	O
to	to	TO	I-NP	O
four	four	CD	I-NP	O
cigarettes	cigarette	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
down	down	RB	B-ADVP	O
from	from	IN	B-PP	O
one	one	CD	B-NP	O
pack	pack	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
significant	significant	JJ	I-NP	O
alcohol	alcohol	NN	I-NP	O
history	history	NN	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
physical	physical	JJ	B-NP	O
examination	examination	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
morbidly	morbidly	RB	I-NP	O
obese	obese	JJ	I-NP	O
woman	woman	NN	I-NP	O
breathing	breathing	NN	I-NP	O
with	with	IN	B-PP	O
difficulty	difficulty	NN	B-NP	O
lying	lie	VBG	B-VP	O
in	in	IN	B-PP	O
bed	bed	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
vital	vital	JJ	I-NP	O
signs	sign	NNS	I-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
temperature	temperature	NN	I-NP	O
of	of	IN	B-PP	O
98.5	98.5	CD	B-NP	O
degrees	degree	NNS	I-NP	O
,	,	,	O	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
98	98	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
110/80	110/80	CD	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
respiratory	respiratory	JJ	I-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
20	20	CD	B-NP	O
,	,	,	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
96	96	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
physical	physical	JJ	I-NP	O
examination	examination	NN	I-NP	O
was	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
following	following	NN	I-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
skin	skin	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
rashes	rash	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
cyanosis	cyanosis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
normocephalic	normocephalic	JJ	B-ADJP	O
,	,	,	O	O
atraumatic	atraumatic	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
nasal	nasal	JJ	I-NP	O
discharge	discharge	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
sinus	sinus	NN	I-NP	O
tenderness	tenderness	NN	I-NP	O
,	,	,	O	O
moist	moist	NN	B-NP	O
,	,	,	O	O
pink	pink	NN	B-NP	O
,	,	,	O	O
mucous	mucous	JJ	B-NP	O
membranes	membrane	NNS	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
exudate	exudate	NN	I-NP	O
or	or	CC	I-NP	O
erythema	erythema	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
neck	neck	NN	I-NP	O
was	be	VBD	B-VP	O
supple	supple	NN	B-NP	O
and	and	CC	O	O
non-tender	non-tender	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
jugular	jugular	JJ	I-NP	O
venous	venous	JJ	I-NP	O
distension	distension	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
thyromegaly	thyromegaly	RB	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
chest	chest	NN	I-NP	O
examination	examination	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
diffuse	diffuse	JJ	B-NP	O
inspiratory	inspiratory	JJ	I-NP	O
and	and	CC	I-NP	O
expiratory	expiratory	JJ	I-NP	O
wheezes	wheeze	VBZ	B-VP	O
bilaterally	bilaterally	RB	B-ADVP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
prolonged	prolonged	JJ	I-NP	O
expiratory	expiratory	JJ	I-NP	O
phase	phase	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
crackles	crackle	NNS	I-NP	O
or	or	CC	I-NP	O
rales	rale	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
diaphragm	diaphragm	NN	I-NP	O
elevated	elevate	VBD	B-VP	O
symmetrically	symmetrically	RB	B-ADVP	O
on	on	IN	B-PP	O
expiration	expiration	NN	B-NP	O
.	.	.	O	O

Cardiac	Cardiac	JJ	B-NP	O
examination	examination	NN	I-NP	O
was	be	VBD	B-VP	O
regular	regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	O	O
S2	S2	NN	B-NP	B-protein
,	,	,	O	O
no	no	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	I-NP	O
gallops	gallop	NNS	I-NP	O
or	or	CC	I-NP	O
rubs	rub	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-NP	O
,	,	,	I-NP	O
obese	obese	JJ	I-NP	O
,	,	,	I-NP	O
non-tender	non-tender	JJ	I-NP	O
with	with	IN	B-PP	O
positive	positive	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
masses	mass	NNS	I-NP	O
were	be	VBD	B-VP	O
palpated	palpate	VBN	I-VP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
examination	examination	NN	I-NP	O
was	be	VBD	B-VP	O
limited	limit	VBN	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
obesity	obesity	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
extremities	extremity	NNS	I-NP	O
were	be	VBD	B-VP	O
warm	warm	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
clubbing	clubbing	NN	I-NP	O
or	or	CC	I-NP	O
cyanosis	cyanosis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
marked	mark	VBN	I-VP	O
edema	edema	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
lower	low	JJR	I-NP	O
extremities	extremity	NNS	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
with	with	IN	B-PP	O
left	leave	VBN	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
right	right	JJ	B-ADJP	O
.	.	.	O	O

Dorsalis	Dorsalis	NNP	B-NP	O
pedis	pedis	NN	I-NP	O
pulses	pulse	NNS	I-NP	O
were	be	VBD	B-VP	O
trace	trace	NN	B-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
:	:	:	O	O
Laboratory	Laboratory	NN	B-NP	O
studies	study	NNS	I-NP	O
were	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
a	a	DT	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
11.3	11.3	NN	B-NP	B-protein
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
36.7	36.7	CD	I-NP	I-protein
and	and	CC	O	O
platelet	platelet	NN	B-NP	B-protein
count	count	NN	I-NP	I-protein
317	317	CD	I-NP	I-protein
.	.	.	O	O

PT	PT	NN	B-NP	O
was	be	VBD	B-VP	O
elevated	elevate	VBN	I-VP	O
at	at	IN	B-PP	O
23.5	23.5	CD	B-NP	O
,	,	,	O	O
PTT	PTT	NN	B-NP	B-protein
42.2	42.2	CD	I-NP	I-protein
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
3.8	3.8	CD	I-NP	I-protein
.	.	.	O	O

Electrolytes	Electrolyte	NNS	B-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
sodium	sodium	NN	I-NP	O
of	of	IN	B-PP	O
141	141	CD	B-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
2.6	2.6	CD	I-NP	O
,	,	,	O	O
chloride	chloride	NN	B-NP	O
102	102	CD	I-NP	O
,	,	,	O	O
bicarbonate	bicarbonate	NN	B-NP	O
26	26	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
17	17	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
0.9	0.9	CD	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
glucose	glucose	NN	I-NP	O
of	of	IN	B-PP	O
108	108	CD	B-NP	O
.	.	.	O	O

Calcium	Calcium	NN	B-NP	O
was	be	VBD	B-VP	O
9.6	9.6	CD	B-NP	O
,	,	,	O	O
magnesium	magnesium	NN	B-NP	O
1.9	1.9	CD	I-NP	O
.	.	.	O	O

Theophylline	Theophylline	NN	B-NP	O
level	level	NN	I-NP	O
was	be	VBD	B-VP	O
14.7	14.7	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
EKG	EKG	NN	I-NP	B-protein
showed	show	VBD	B-VP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
95	95	CD	B-NP	O
beats	beat	NNS	I-NP	O
per	per	IN	B-PP	O
minute	minute	NN	B-NP	O
.	.	.	O	O

PR	PR	NN	B-NP	B-protein
,	,	,	I-NP	O
QRS	QRS	NN	I-NP	B-protein
and	and	CC	I-NP	O
QTC	QTC	NN	I-NP	O
intervals	interval	NNS	I-NP	O
were	be	VBD	B-VP	O
all	all	DT	O	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
,	,	,	O	O
PA	PA	NN	B-NP	O
and	and	CC	O	O
lateral	lateral	JJ	B-ADJP	O
,	,	,	O	O
showed	show	VBD	B-VP	O
low	low	JJ	B-NP	O
lung	lung	NN	I-NP	O
volumes	volume	NNS	I-NP	O
but	but	CC	O	O
no	no	DT	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
or	or	CC	O	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
Respiratory	Respiratory	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
symptoms	symptom	NNS	I-NP	O
were	be	VBD	B-VP	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
asthma	asthma	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
bronchitis	bronchitis	NN	B-NP	O
given	give	VBN	B-VP	O
her	her	PRP$	B-NP	O
long-standing	long-standing	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
asthma	asthma	NN	B-NP	O
and	and	CC	O	O
chronic	chronic	JJ	B-NP	O
obstructive	obstructive	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
recent	recent	JJ	I-NP	O
exposure	exposure	NN	I-NP	O
to	to	TO	B-PP	O
mold	mold	NN	B-NP	O
and	and	CC	I-NP	O
dust	dust	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
embolus	embolus	NN	I-NP	O
was	be	VBD	B-VP	O
deemed	deem	VBN	I-VP	O
less	less	RBR	B-ADJP	O
likely	likely	JJ	I-ADJP	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
of	of	IN	B-PP	O
3.8	3.8	CD	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
of	of	IN	B-PP	O
96	96	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Prednisone	Prednisone	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
medical	medical	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
included	include	VBD	B-VP	O
Uniphyl	Uniphyl	NNP	B-NP	O
800	800	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Albuterol	Albuterol	NNP	B-NP	O
nebulizers	nebulizer	VBZ	B-VP	O
2.5	2.5	CD	B-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

and	and	CC	O	O
q.	q.	NN	B-NP	O
1h	1h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
,	,	,	O	O
Flovent	Flovent	NNP	B-NP	O
660	660	CD	I-NP	O
mcg	mcg	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
Flonase	Flonase	NNP	B-NP	O
1-2	1-2	CD	I-NP	O
sprays	spray	NNS	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
Serevent	Serevent	NN	B-NP	B-protein
2	2	CD	B-NP	I-protein
puffs	puff	NNS	I-NP	I-protein
b.i.d.	b.i.d.	RB	B-ADVP	O
and	and	CC	O	O
Atrovent	Atrovent	NNP	B-NP	O
nebulizers	nebulizer	NNS	I-NP	O
q.i.d.	q.i.d.	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
Levofloxacin	Levofloxacin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remains	remain	VBZ	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
sputum	sputum	NN	I-NP	B-protein
culture	culture	NN	I-NP	I-protein
grew	grow	VBD	B-VP	I-protein
out	out	RP	B-PRT	I-protein
4	4	CD	B-NP	I-protein
+	+	SYM	I-NP	O
polys	poly	NNS	I-NP	O
,	,	,	O	O
moderate	moderate	JJ	B-NP	O
gram	gram	NN	I-NP	O
,	,	,	O	O
positive	positive	JJ	B-NP	O
variable	variable	JJ	I-NP	O
cocci	coccus	NNS	I-NP	O
in	in	IN	B-PP	O
clusters	cluster	NNS	B-NP	O
and	and	CC	O	O
few	few	JJ	B-NP	O
gram	gram	NN	I-NP	O
negative	negative	JJ	I-NP	O
rods	rod	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
improve	improve	VB	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
medical	medical	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
with	with	IN	B-PP	O
continued	continued	JJ	B-NP	O
cough	cough	NN	I-NP	O
and	and	CC	I-NP	O
sputum	sputum	NN	I-NP	O
production	production	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
two	two	CD	B-NP	O
liters	liter	NNS	I-NP	O
oxygen	oxygen	NN	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
on	on	IN	B-PP	O
August	August	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
overnight	overnight	JJ	I-NP	O
for	for	IN	B-PP	O
comfort	comfort	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
peak	peak	JJ	I-NP	O
flow	flow	NN	I-NP	O
was	be	VBD	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
120	120	CD	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
and	and	CC	O	O
improved	improve	VBN	B-VP	O
to	to	TO	B-PP	O
240	240	CD	B-NP	O
on	on	IN	B-PP	O
May	May	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
,	,	,	O	O
230	230	CD	B-NP	O
on	on	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
and	and	CC	O	O
peak	peak	JJ	B-NP	O
flow	flow	NN	I-NP	O
of	of	IN	B-PP	O
320	320	CD	B-NP	O
on	on	IN	B-PP	O
May	May	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
remained	remain	VBD	B-VP	O
short	short	JJ	B-ADJP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
although	although	IN	B-SBAR	O
this	this	DT	B-NP	O
improved	improve	VBD	B-VP	O
over	over	IN	B-PP	O
her	her	PRP$	B-NP	O
course	course	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
also	also	RB	B-ADVP	O
improved	improve	VBD	B-VP	O
in	in	IN	B-PP	O
movement	movement	NN	B-NP	O
with	with	IN	B-PP	O
diminished	diminish	VBN	B-NP	O
wheezing	wheezing	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
peak	peak	NN	I-NP	O
flow	flow	NN	I-NP	O
of	of	IN	B-PP	O
320	320	CD	B-NP	O
,	,	,	O	O
saturating	saturate	VBG	B-VP	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
respiratory	respiratory	JJ	I-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
20	20	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
today	today	NN	B-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
,	,	,	O	O
continuing	continue	VBG	B-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
nebulizers	nebulizer	NNS	I-NP	O
and	and	CC	I-NP	O
inhalers	inhaler	NNS	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
the	the	DT	B-NP	O
Prednisone	Prednisone	NN	I-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
today	today	NN	B-NP	O
,	,	,	O	O
day	day	NN	B-NP	O
five	five	CD	I-NP	O
and	and	CC	O	O
then	then	RB	O	O
continuing	continue	VBG	B-VP	O
a	a	DT	B-NP	O
slow	slow	JJ	I-NP	O
taper	taper	NN	I-NP	O
thereafter	thereafter	RB	B-ADVP	O
with	with	IN	B-PP	O
50	50	CD	B-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
times	time	NNS	I-NP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
40	40	CD	B-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
times	time	NNS	I-NP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
30	30	CD	B-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
times	time	NNS	I-NP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
20	20	CD	B-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
times	time	NNS	I-NP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
and	and	CC	O	O
10	10	CD	B-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
times	time	NNS	I-NP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
-RRB-	-RRB-	:	O	O
Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
Levofloxacin	Levofloxacin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

Today	Today	NN	B-NP	O
is	be	VBZ	B-VP	O
day	day	NN	B-NP	O
number	number	NN	I-NP	O
five	five	CD	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
complete	complete	VB	I-VP	O
a	a	DT	B-NP	O
seven	seven	CD	I-NP	O
day	day	NN	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
Levofloxacin	Levofloxacin	NN	B-NP	O
at	at	IN	B-PP	O
her	her	PRP$	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
.	.	.	O	O

3	3	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Hematology	Hematology	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
INR	INR	NN	I-NP	B-protein
of	of	IN	B-PP	O
3.8	3.8	CD	B-NP	O
on	on	IN	B-PP	O
9	9	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
of	of	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
upon	upon	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
known	know	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
increased	increase	VBN	I-NP	O
INR	INR	NN	I-NP	B-protein
with	with	IN	B-PP	O
the	the	DT	B-NP	O
addition	addition	NN	I-NP	O
of	of	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
due	due	JJ	B-PP	O
to	to	TO	B-PP	O
decreased	decrease	VBN	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
clearance	clearance	NN	I-NP	O
.	.	.	O	O

Thus	Thus	RB	B-ADVP	O
,	,	,	O	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
decreased	decrease	VBD	B-VP	O
her	her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
to	to	TO	B-PP	O
8	8	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
on	on	IN	B-PP	O
January	January	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
climbed	climb	VBD	B-VP	O
to	to	TO	B-PP	O
5.0	5.0	CD	B-NP	O
,	,	,	O	O
so	so	IN	O	O
we	we	PRP	B-NP	O
again	again	RB	B-ADVP	O
reduced	reduce	VBD	B-VP	O
her	her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
to	to	TO	B-PP	O
6	6	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
evening	evening	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
2.0	2.0	CD	B-NP	O
on	on	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
again	again	RB	I-VP	O
raised	raise	VBN	I-VP	O
to	to	TO	B-PP	O
9	9	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
On	On	IN	B-PP	O
May	May	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
4.5	4.5	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
AM	AM	NNP	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
was	be	VBD	B-VP	O
ordered	order	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
held	hold	VBN	I-VP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
readjusted	readjust	VBN	I-VP	O
to	to	TO	B-PP	O
7	7	CD	B-NP	O
mg	mg	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
AM	AM	NN	I-NP	O
and	and	CC	O	O
8	8	CD	B-NP	O
mg	mg	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
PM	PM	NN	I-NP	O
while	while	IN	B-SBAR	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
ordered	order	VBN	I-VP	O
for	for	IN	B-PP	O
two	two	CD	B-NP	O
more	more	JJR	I-NP	O
days	day	NNS	I-NP	O
of	of	IN	B-PP	O
Levofloxacin	Levofloxacin	NN	B-NP	O
and	and	CC	B-NP	O
then	then	RB	I-NP	O
two	two	CD	B-NP	O
days	day	NNS	I-NP	O
after	after	IN	B-SBAR	O
she	she	PRP	B-NP	O
stopped	stop	VBD	B-VP	O
the	the	DT	B-NP	O
Levofloxacin	Levofloxacin	NN	I-NP	O
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
should	should	MD	B-VP	O
be	be	VB	I-VP	O
rechecked	rechecke	VBN	I-VP	O
and	and	CC	O	O
Coumadin	Coumadin	NN	B-NP	O
dose	dose	NN	I-NP	O
readjusted	readjust	VBD	B-VP	O
to	to	TO	B-PP	O
9	9	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
with	with	IN	B-PP	O
INR	INR	NN	B-NP	B-protein
being	be	VBG	B-VP	O
checked	check	VBN	I-VP	O
every	every	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

4	4	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
Fluids	Fluid	NNS	I-NP	O
,	,	,	O	O
electrolytes	electrolyte	NNS	B-NP	O
and	and	CC	O	O
nutrition	nutrition	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBN	B-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
reduction	reduction	NN	I-NP	O
medications	medication	NNS	I-NP	O
including	include	VBG	B-PP	O
Xenical	Xenical	JJ	B-NP	O
120	120	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
and	and	CC	O	O
Adipex	Adipex	NN	B-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
Phentermine	Phentermine	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
restarted	restart	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
weight	weight	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
395.2	395.2	CD	B-NP	O
pounds	pound	NNS	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Albuterol	Albuterol	NNP	I-NP	O
nebulizers	nebulizer	NNS	I-NP	O
2.5	2.5	CD	B-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

2	2	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Albuterol	Albuterol	NNP	I-NP	O
nebulizers	nebulizer	VBZ	B-VP	O
2.5	2.5	CD	B-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
1h	1h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	NN	B-NP	O
wheezing	wheezing	NN	I-NP	O
or	or	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

3	3	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
TUMS	TUMS	NN	I-NP	O
625	625	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
4	4	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Diazide	Diazide	NN	I-NP	O
one	one	CD	B-NP	O
capsule	capsule	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
systolic	systolic	JJ	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
lower	low	JJR	B-ADJP	O
than	than	IN	B-PP	O
100	100	CD	B-NP	O
.	.	.	O	O

5	5	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Ferrous	Ferrous	JJ	I-NP	O
sulfate	sulfate	NN	I-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
6	6	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Folate	Folate	NN	I-NP	O
3	3	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Lasix	Lasix	NN	I-NP	B-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Magnesium	Magnesium	NNP	I-NP	I-protein
oxide	oxide	NN	I-NP	I-protein
840	840	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
9	9	CD	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
Prednisone	Prednisone	NN	I-NP	I-protein
60	60	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
10	10	CD	I-NP	I-protein
-RRB-	-RRB-	:	O	I-protein
Pyridoxine	Pyridoxine	NN	B-NP	I-protein
50	50	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Uniphyl	Uniphyl	NNP	I-NP	O
800	800	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
12	12	CD	I-NP	O
-RRB-	-RRB-	SYM	O	O
Coumadin	Coumadin	NN	B-NP	O
8	8	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	VBG	B-VP	O
AM	AM	NN	B-NP	O
,	,	,	O	O
7	7	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NNP	I-NP	O
PM	PM	NNP	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
two	two	CD	B-NP	O
days	day	NNS	I-NP	O
off	off	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
,	,	,	O	O
will	will	MD	B-VP	O
change	change	VB	I-VP	O
dose	dose	NN	B-NP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
9	9	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
13	13	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Atrovent	Atrovent	NNP	I-NP	O
nebulizers	nebulizer	NNS	I-NP	O
0.5	0.5	CD	B-NP	O
mg	mg	NN	I-NP	O
q.i.d.	q.i.d.	RB	B-NP	O
14	14	CD	I-NP	O
-RRB-	-RRB-	SYM	I-NP	O
Serevent	Serevent	NN	I-NP	O
2	2	CD	B-NP	O
puffs	puff	NNS	I-NP	O
inhaler	inhal	JJR	B-NP	O
b.i.d.	b.i.d.	NN	I-NP	B-protein
15	15	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Flovent	Flovent	NNP	I-NP	I-protein
660	660	CD	I-NP	I-protein
mcg	mcg	NN	I-NP	I-protein
inhaler	inhaler	NN	I-NP	I-protein
b.i.d.	b.i.d.	RB	B-NP	I-protein
16	16	CD	I-NP	I-protein
-RRB-	-RRB-	HYPH	I-NP	I-protein
Flonase	Flonase	NN	I-NP	I-protein
1-2	1-2	NN	I-NP	O
sprays	spray	NNS	I-NP	O
inhaled	inhale	VBD	B-VP	O
q.	q.	NN	B-NP	O
day	day	NN	I-NP	O
to	to	TO	B-PP	O
each	each	DT	B-NP	O
nostril	nostril	NN	I-NP	O
.	.	.	O	O

17	17	CD	B-NP	O
-RRB-	-RRB-	SYM	I-NP	O
Levofloxacin	Levofloxacin	NN	I-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
times	time	NNS	I-NP	O
three	three	CD	B-NP	O
days	day	NNS	I-NP	O
starting	start	VBG	B-PP	O
today	today	NN	B-NP	O
.	.	.	O	O

18	18	CD	B-NP	O
-RRB-	-RRB-	SYM	I-NP	O
Wellbutrin	Wellbutrin	NN	I-NP	B-protein
200	200	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
19	19	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Celebrex	Celebrex	NNP	I-NP	I-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	I-NP	I-protein
b.i.d.	b.i.d.	FW	I-NP	I-protein
20	20	CD	I-NP	I-protein
-RRB-	-RRB-	HYPH	B-NP	I-protein
Xenical	Xenical	JJ	I-NP	I-protein
120	120	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
21	21	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Adipex	Adipex	NNP	I-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

22	22	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Potassium	Potassium	NN	I-NP	O
chloride	chloride	NN	I-NP	O
slow	slow	JJ	I-NP	O
release	release	NN	I-NP	O
20	20	CD	I-NP	O
mEq	mEq	NN	I-NP	O
times	time	NNS	I-NP	O
two	two	CD	B-NP	O
p.o.	p.o.	FW	I-NP	O
t.i.d.	t.i.d.	FW	I-NP	O
CONDITION	CONDITION	NN	I-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
.	.	.	O	O

FOLLOW-UP	FOLLOW-UP	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
follow-up	follow-up	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Gyurko	Gyurko	NNP	I-NP	O
on	on	IN	B-PP	O
March	March	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
scheduled	schedule	VBN	I-VP	O
and	and	CC	O	O
a	a	DT	B-NP	O
follow-up	follow-up	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Stenbeck	Stenbeck	NNP	I-NP	O
on	on	IN	B-PP	O
May	May	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
also	also	RB	I-VP	O
scheduled	schedule	VBN	I-VP	O
.	.	.	O	O

Dictated	Dictate	VBN	B-VP	O
By	By	IN	B-PP	O
:	:	:	O	O
BEYLOTTE	BEYLOTTE	NN	B-NP	O
III	III	CD	I-NP	O
,	,	,	O	O
ALI	ALI	NNP	B-NP	O
CLEMENT	CLEMENT	NNP	I-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
HARLAND	HARLAND	NNP	B-NP	O
H.	H.	NNP	I-NP	O
DENTREMONT	DENTREMONT	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
GI4	GI4	NNP	I-NP	O
AS399/1404	AS399/1404	NNP	I-NP	O
Batch	Batch	NNP	I-NP	O
:	:	:	O	O
8849	8849	CD	B-NP	O
Index	Index	NNP	I-NP	O
No	No	NNP	I-NP	O
.	.	.	O	O

JQQI225BWL	JQQI225BWL	NN	B-NP	O
D	D	NN	I-NP	O
:	:	:	O	O
6/3	6/3	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
6/3	6/3	CD	B-NP	O
CC	CC	NN	I-NP	O
:	:	:	O	O
TOD	TOD	NN	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
CENTER	CENTER	NNP	I-NP	O
,	,	,	O	O
Choirv	Choirv	NNP	B-NP	O
ZACK	ZACK	NNP	I-NP	O
R.	R.	NNP	I-NP	O
GABBAMONTE	GABBAMONTE	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
JJ81	JJ81	NNP	I-NP	O
DR.	DR.	NNP	I-NP	O
DILMORE	DILMORE	NNP	I-NP	O
,	,	,	O	O
ROBIN	ROBIN	NNP	B-NP	O
FLOSS	FLOSS	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
MX7	MX7	NNP	I-NP	O

